follicular lymphoma Archives -

Reeling from the recent failure of its lead product in a pivotal trial, Nordic Nanovector has formally started

Troubled Nordic Nanovector “exploring strategic options”

https://pharmaphorum.com/news/troubled-nordic-nanovector-exploring-strategic-options/

Market Access/ News/ News/ News/ Oncology

FDA to decide on Roche’s lymphoma drug Lunsumio before year-end

Phil Taylor follicular lymphoma, immuno-oncology, Lunsumio, non-Hodgkin lymphoma, Oncology, Roche 0 Comment

The FDA has granted a priority review to Roche’s T-cell engager Lunsumio as a treatment for follicular lymphoma

FDA to decide on Roche’s lymphoma drug Lunsumio before year-end

https://pharmaphorum.com/news/fda-to-decide-on-roches-lymphoma-drug-lunsumio-before-year-end/

Market Access/ News/ News

Gilead tries again with twice-yearly HIV drug lenacapavir

Phil Taylor follicular lymphoma, Gilead Sciences, HIV, infectious disease, lenacapavir, Oncology, Rukobia, ViiV Healthcare, Yescarta 0 Comment

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to

Gilead tries again with twice-yearly HIV drug lenacapavir

https://pharmaphorum.com/news/gilead-tries-again-with-twice-yearly-hiv-drug-lenacapavir/

Market Access/ News/ News/ News/ Oncology

EU first to clear Roche’s lymphoma bispecific mosunetuzumab

Phil Taylor follicular lymphoma, immuno-oncology, Lunsumio, mosunetuzumab, non-Hodgkin lymphoma, Oncology, regulatory approval, Roche 0 Comment

Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for

EU first to clear Roche’s lymphoma bispecific mosunetuzumab

https://pharmaphorum.com/news/eu-first-to-clear-roches-lymphoma-bispecific-mosunetuzumab/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

News/ News/ Oncology

Epizyme scores important follicular lymphoma approval with Tazverik

Richard Staines cancer, Epizyme, follicular lymphoma, R&D, Tazverik 0 Comment

Epizyme has scored an important FDA win after the regulator approved its Tazverik (tazemetostat) in follicular lymphoma. Tazverik is already approved in

Epizyme scores important follicular lymphoma approval with Tazverik

https://pharmaphorum.com/news/epizyme-unlocks-more-sales-with-tazverik-follicular-lymphoma-approval/

News/ News/ Oncology/ Top stories

FDA hastens development of Novartis’ Kymriah in follicular lymphoma

Richard Staines blood cancer, cancer, CAR T, fda, follicular lymphoma, Kymriah, Novartis, R&D, regulation 0 Comment

Novartis will receive extra help from the FDA during the development of its CAR-T cancer cell therapy Kymriah

FDA hastens development of Novartis’ Kymriah in follicular lymphoma

https://pharmaphorum.com/news/fda-hastens-development-of-novartis-kymriah-in-follicular-lymphoma/

Market Access/ News/ News/ News/ Oncology

NICE backs Celgene’s Revlimid for chemo-free lymphoma therapy

Phil Taylor Bristol-Myers Squibb, Celgene, follicular lymphoma, NICE, non-Hodgkin lymphoma, Revlimid 0 Comment

NICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a

NICE backs Celgene’s Revlimid for chemo-free lymphoma therapy

https://pharmaphorum.com/news/embargo-001-27-feb-nice-backs-celgenes-revlimid-for-chemo-free-lymphoma-therapy/

News/ News/ Oncology

Epizyme eyes lucrative use for newly-launched Tazverik

Richard Staines cancer, Constellation Pharmaceuticals, fda, follicular lymphoma, non-Hodgkin lymphoma, Pfizer, tazemetostat, Tazverik 0 Comment

US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the

Epizyme eyes lucrative use for newly-launched Tazverik

https://pharmaphorum.com/news/epizyme-eyes-lucrative-use-for-newly-launched-tazverik/

Cancer/ News/ US

Fast review for Bayer’s copanlisib in lymphoma

Richard Staines Bayer, cancer, Epizime, fda, follicular lymphoma, lymphoma 0 Comment

Drug gets fast review in tough to treat follicular lymphoma

Fast review for Bayer’s copanlisib in lymphoma

https://pharmaphorum.com/news/copanlisib/

Trending

follicular lymphoma

Login